Medical Excellence Capital

Medical Excellence Capital (MEC) is an early-stage life sciences venture fund headquartered in Nissequogue, NY, founded in 2020 by John Prufeta. The firm pairs experienced investment professionals and operators with a proprietary network of over 1,200 physician-scientists spanning 33 major academic medical centers. MEC focuses on precision health innovations addressing large unmet medical needs, with particular emphasis on cell therapy, gene therapy, synthetic biology, regenerative medicine, and AI/ML applied to drug discovery. Current areas of high interest include inflammation and immunology, allergy, cardiovascular disease, precision oncology, and neuropsychiatry. MEC closed its inaugural fund (Fund I) at $145 million in August 2022 and is actively investing out of its second fund, with approximately $300 million under management. The firm targets Seed to Series A opportunities, prefers to lead or co-lead rounds, and takes active board roles in portfolio companies. Portfolio companies include Aspen Neuroscience, ProJenX, TwoStep Therapeutics, Immunitas Therapeutics, Nobias Therapeutics, and Pleno Inc.